Title:
TREATING DRUG ADDICTION AND PREVENTING DRUG RELAPSE
Document Type and Number:
WIPO Patent Application WO/2013/188465
Kind Code:
A3
Abstract:
The present invention relates to pharmaceutical compositions comprising (a) a pharmaceutically effective amount of an mGluR5 positive allosteric modulator, derivative, prodrug or a pharmaceutically acceptable salt thereof; (b) a pharmaceutically effective amount of an agent selected from an NMDA partial agonist or a GlyT1 inhibitor, derivative, prodrug or a pharmaceutically acceptable salt thereof; and (c) a pharmaceutically acceptable carrier. The present invention also relates to methods for treating drug addiction and preventing a drug relapse in a patient. The methods comprise (a) administering to the patient a pharmaceutically effective amount of an mGluR5 positive allosteric modulator, derivative, prodrug or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof; (b) administering to the patient a pharmaceutically effective amount of an agent selected from an NMDA partial agonist or a GlyT1 inhibitor, derivative, prodrug or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof.
Inventors:
OLIVE M FOSTER (US)
Application Number:
PCT/US2013/045268
Publication Date:
January 30, 2014
Filing Date:
June 11, 2013
Export Citation:
Assignee:
UNIV ARIZONA (US)
OLIVE M FOSTER (US)
OLIVE M FOSTER (US)
International Classes:
A61K31/506; A61K31/695
Foreign References:
| US20120028956A1 | 2012-02-02 | |||
| US20120046232A1 | 2012-02-23 |
Other References:
GASS, JT ET AL.: "Positive allosteric modulation of mGluR5 receptors facilitates extinction of a cocaine contextual memory", BIOLOGICAL PSYCHIATRY, vol. 65, no. 8, 15 April 2009 (2009-04-15)
GASTAMBIDE, F ET AL.: "Selective Remediation of Reversal Learning Deficits in the Neurodevelopmental MAM Model of Schizophrenia by a Novel mGlu5 Positive Allosteric Modulator", NEUROPSYCHOPHARMACOLOGY, vol. 37, 30 November 2011 (2011-11-30), Retrieved from the Internet [retrieved on 20131109]
CLEVA, RM ET AL.: "Positive Allosteric Modulators of Type 5 Metabotropic Glutamate Receptors (mGluR5) and Their Therapeutic Potential for the Treatment of CNS Disorders", MOLECULES, vol. 16, 2 March 2011 (2011-03-02), pages 2097 - 2106
GASTAMBIDE, F ET AL.: "Selective Remediation of Reversal Learning Deficits in the Neurodevelopmental MAM Model of Schizophrenia by a Novel mGlu5 Positive Allosteric Modulator", NEUROPSYCHOPHARMACOLOGY, vol. 37, 30 November 2011 (2011-11-30), Retrieved from the Internet
CLEVA, RM ET AL.: "Positive Allosteric Modulators of Type 5 Metabotropic Glutamate Receptors (mGluR5) and Their Therapeutic Potential for the Treatment of CNS Disorders", MOLECULES, vol. 16, 2 March 2011 (2011-03-02), pages 2097 - 2106
Attorney, Agent or Firm:
HORAN, Nina R. et al. (11 Broadway Suite 111, New York New York, US)
Download PDF:
Previous Patent: MULTIPLE DEPTH PLANE THREE-DIMENSIONAL DISPLAY USING A WAVE GUIDE REFLECTOR ARRAY PROJECTOR
Next Patent: TRAVEL ADVISORY NOTIFICATIONS
Next Patent: TRAVEL ADVISORY NOTIFICATIONS